A view from the Center


Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Forging a new path to commercialization for cell and gene therapies

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which present unique challenges to pharma companies’ current technology systems.

Read more

Safety first: Technology and analytics could help transform pharmacovigilance

by Kelly Traverso, Life Sciences R&D, Deloitte Consulting LLP

Sometimes a relatively small investment can lead to the development of a product or process that benefits a company, an industry, or even society as a whole. The three-point seat belt, for example, is a simple strap of nylon webbing that protects drivers and passengers from being injured in an accident. This innovation helped to transform safety standards in the automotive industry and has saved millions of lives.

Read more

Can our paper-based clinical-trial model make the jump to the virtual world?

by Dawn Anderson, Managing director, Deloitte Consulting LLP

I entered the pharmaceutical sector 32 years ago as a clinical research associate. In all that time, there has been surprisingly little change to the way biopharmaceutical companies and contract research organizations conduct clinical trials. While digital technology is widely available to the general population, it generally has not made its way into clinical trials.

Read more

Here’s how to make virtual health a pillar of your health plan members’ experience

by Felix Matthews, MD, MBA and Ken Abrams, MD, MBA, Deloitte Consulting LLP

Nearly all health plans (94 percent) offer virtual health services, and 96 percent expect their reliance on this technology will grow, according to the results of a survey conducted by America’s Health Insurance Plans (AHIP).1 However, despite being widely available, virtual health has generally not been embraced by health plan members. One of the most formidable barriers to adoption might be the members themselves.

Read more

What would a future with longer health span mean for end of life?

by Claire Cruse, Health Policy Manager, Deloitte Center for Health Solutions, Deloitte Services LP

It’s not a topic that most of us enjoy thinking or talking about. But it’s a reality I faced at the age of 13 and will face again in July—the 20th anniversary of my mother’s death. It’s something that we all must acknowledge at some point in our lives: None of us will be around forever.

Read more

Can the world’s biggest companies save health care?

by Margaret Anderson, Managing Director, Deloitte Consulting LLP

It’s no secret that we often don’t get what we pay for when it comes to health care. While we spend upwards of $3.5 trillion a year for health care in the US1, our longevity, infant and child mortality, and maternal mortality fall behind other countries.2 Eric Topol, author of the book Deep Medicine,

Read more